Mast cell phenotype in benign and malignant tumors of the prostate

Polish Journal of Pathology

Volumn 65, Issue 2, 2014, Pages 147-153

  Globa, Tatiana ^a   Şptefrţi, Lilian ^a   Ceauşu, Raluca Amalia ^b   Gaje, Puşa ^b   Cimpean, Anca Maria ^b   Raica, Marius ^b  

^a STATE UNIVERSITY OF MEDICINE AND PHARMACY NICOLAE TESTEMITANU   (Moldova)

^b Angiogenesis Research Center   (Romania)

Author keywords

CD117 (c kit); Chymase; Prostate cancer; Prostatic benign hyperplasia; Tryptase positive mast cells

Indexed keywords

CHYMASE; STEM CELL FACTOR RECEPTOR; TRYPTASE; TUMOR MARKER;

ARTICLE; BIOPSY; CANCER GRADING; ENZYMOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MALE; MAST CELL; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROSTATE HYPERTROPHY; PROSTATE TUMOR;

BIOPSY; CHYMASES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAST CELLS; NEOPLASM GRADING; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT; TRYPTASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84905164904     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: 10.5114/pjp.2014.43965     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics. CA Cancer J Clin 2010; 60: 277-300.
2. Dvorak AM. Human mast cells. Adv Anat Embryol Cell Biol 1989; 114: 1-107.
3. Galli SJ. Biology of disease: new insights into "the riddle of the mast cells": microenvironmental regulation of mast cell development and phenotypic heterogeneity. Pathology Reviews 1990; 49-77.
4. Galli SJ. New concepts about the mast cell. N Engl J Med 1993; 328: 257-265.
5. Weidner N, Austen KF. Ultrastructural and immunohistochemical characterization of normal mast cells at multiple body sites. J Invest Dermatol 1991; 96: 26S-31S.
6. Theoharides TC, Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 2004; 25: 235-241.
7. Maltby S, Khazaie K, McNagny KM. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 2009; 1796: 19-26.
8. Aydin O, Dusmez D, Cinel L, et al. Immunohistological analysis of mast cell numbers in the intratumoral and peritumoral regions of prostate carcinoma compared to benign prostatic hyperplasia. Pathol Res Pract 2002; 198: 267-271.
9. Cordon Cardo C, Simak R, Capodieci P, et al. Expression of c-kit and kit-ligand in benign and malignant prostatic tissues. Histol Histopathol 2000; 15: 365-374.
10. Fleischmann A, Schlomm T, Köllermann J, et al. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate 2009; 69: 976-981.
11. Nonomura N, Takayama H, Nishimura K, et al. Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br J Cancer 2007; 97: 952-956.
12. Sari A, Serel TA, Candir O, et al. Mast cell variations in tumour tissue and with histopathological grading in specimens of prostatic adenocarcinoma. BJU Int 1999; 84: 851-853.
13. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
14. Liotta LA, Kohn EC. The microenvironment of the tumour- host interface. Nature 2001; 411: 375-379.
15. Matrisian LM, Cunha GR, Mohla S. Epithelial-stromal interactions and tumor progression: meeting summary and future directions. Cancer Research 2001; 61: 3844-3846.
16. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today 2000; 6: 324-329.
17. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol 2001; 166: 2472-2483.
18. Dyduch G, Okoń K, Pescarini E. Mast cells in melanocytic skin lesions. An immunohistochemical and quantitative study. Pol J Pathol 2011; 62: 139-144.
19. Pyziak L, Stasikowska-Kanicka O, Danilewicz M, et al. Immunohistochemical analysis of mast cell infiltrates and microvessel density in oral squamous cell carcinoma. Pol J Pathol 2013; 64: 276-280.
20. Farram E, Nelson DS. Mouse mast cells as anti-tumor effector cells. Cellular Immunology 1980; 55: 294-301.
21. Ghiara P, Boraschi D, Scapigliati G, et al. In vitro generated mast cells express natural cytotoxicity against tumor cells. Immunology 1985; 55: 317-324.
22. Henderson WR, Chi EY, Jong EC, et al. Mast cell-mediated tumor cell cytotoxicity. Role of the peroxidase system. JEM 1981; 153: 520-533.
23. Dyduch G, Kaczmarczyk K, Okoń K. Mast cells and cancer: enemies or allies? Pol J Pathol 2012; 63: 1-7.
24. Dimitriadou V, Koutsilieris M. Mast cell-tumor cell interactions: for or against tumor growth and metastasis? Anticancer Res 1997; 17: 1541-1549.
25. Masaki T, Matsuzaki Y, Onitsuka T. Correlation between mast cells and survival rates in patients with pulmonary adenocarcinoma. Lung Cancer 1999; 26: 103-108.
26. Stawerski P, Wagrowska-Danilewicz M, Stasikowska-Kanicka O, et al. Augmented mast cell infiltration and microvessel density in prostate cancer. Contemp Oncol (Pozn) 2013; 17: 378-382.
27. Białas M, Dyduch G, Szpor J, et al. Microvascular density and mast cells in benign and malignant pheochromocytomas. Pol J Pathol 2012; 63: 235-242.
28. Smithey BE, Pappo AS, Hill DA. C-kit expression in pediatric solid tumors: a comparative immunohistochemical study. Am J Surg Pathol 2002; 26: 486-492.
29. Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohisto-chemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1-12.
30. Galinsky DS, Nechushtan H. Mast cells and cancer - no longer just basic science. Crit Rev Oncol Hematol 2008; 68: 115-130.
31. Khazaie K, Blatner NR, Khan MW, et al. The significant role of mast cells in cancer. Cancer Metastasis Rev 2011; 30: 45-60.
32. Johansson A, Rudolfsson S, Hammarsten P, et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol 2010; 177: 1031-1041.
33. Paola P, Mario Paolo C. The dark side of mast cell-targeted therapy in prostate cancer. Cancer Res 2012; 72: 831-835.
34. Maaninka K, Lappalainen J, Kovanen PT. Human mast cells arise from a common circulating progenitor. J Allergy Clin Immunol 2013; 132: 463-469.
35. Moon TC, St Laurent CD, Morris KE, et al. Advances in mast cell biology: new understanding of heterogeneity and function. Mucosal Immunol 2010; 3: 111-128.
36. Valent P, Cerny-Reiterer S, Herrmann H, et al. Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. Best Pract Res Clin Haematol 2010; 23: 369-378.